Introduction
Real-time quantitative polymerase chain reaction (RQ-PCR) provides an appropriate monitoring strategy for patients with BCR-ABL expressing chronic myeloid leukaemia (CML). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] The analysis is particularly relevant in the era of imatinib therapy where the achievement of a major molecular response (MMR) is associated with a high progression-free survival. 11 The number of centres providing RQ-PCR analysis is therefore rapidly expanding and various techniques and control genes are in use. PCR requires some technical knowledge for effective implementation and RQ-PCR should not be applied casually. It is not widely appreciated that the RQ-PCR technique potentially produces highly variable quantitative data which may effect the validity of results. 12 Even with a common plasmid calibration standard and standardized protocol, there was approximately 60% coefficient of variation (CV) among laboratories when BCR-ABL was measured by RQ-PCR (Mueller et al. Blood 2005; 106: 563; abstract). Inter-laboratory variables will therefore have an impact on the efforts to achieve harmonized quantitative data.
Conversion of local laboratory BCR-ABL values to an International Scale has been proposed to allow alignment of data and reduce the variability across laboratories. 13 Furthermore, a series of recommendations for producing reliable RQ-PCR data were made. Three control genes, ABL, BCR and GUSB, were recommended as satisfying the criteria for producing reliable data. Hydrolysis or hybridization probes were deemed suitable for appropriate assay design. Primers and probes should be RNA specific and avoid hybridization at the polymorphic site in BCR exon. 13 Strict precautions for avoiding contamination were detailed. These recommendations were justified in the paper, however certain other recommendations warrant a more detailed justification and supporting data. The current review provides the rationale behind specific recommendations, which particularly focuses on the appropriate sample for analysis, the effect of PCR amplification efficiency on the accuracy of results, the importance of monitoring the performance of analysis with quality control samples and the significance of documenting measurement reliability for appropriate clinical decision making.
Appropriate sample for analysis and RNA extraction
The quality of the RNA template is possibly the most important determinant of reproducibility and the biological significance of subsequent results.
14 High-quality RNA is essential because degraded RNA or RNA containing impurities will perform poorly in most enzymatic applications. When ethylenediaminetetraacetic acid (EDTA) blood is stored at ambient temperature, BCR-ABL transcripts degrade by approximately 20% within 24 h and over 50% by 48 h. 15 It is therefore desirable to process blood into an RNA stabilization solution soon after collection, particularly for minimal residual disease testing.
RNA extracted from peripheral blood (PB) and bone marrow (BM) has been used to monitor treatment response and results were concordant using the Europe against Cancer Program (EAC) protocol and in other studies. 8, 9, 16 However, some patients have a consistent difference between PB and BM. In a comparative study performed by the Adelaide group of PB and BM collected in EDTA in 24 newly diagnosed CML patients in chronic phase, three patients had consistent differences in BCR-ABL that were significant and 11 other patients had at least one pair of values that were not concordant. Representative examples of the simultaneous analysis of PB and BM BCR-ABL transcripts in individual patients are shown in Figure 1 . The data suggest that one tissue type be used when monitoring treatment response by sequential analysis. An interchange of PB and BM values at different time points in some patients could lead to the false impression of a real change in the BCR-ABL level. Furthermore, blood may be preferable as the routine sample to follow because it is likely to be more readily available as a replacement if a poor quality sample is received.
Reverse transcription
The pre-RQ-PCR steps, in particular the reverse transcription (RT), are the source of most variation and require careful optimization. [16] [17] [18] The efficiency of the RT is also a critical determinant for sensitivity and reproducibility. Therefore, the choice of enzyme and priming strategy have a profound effect on the yield of cDNA. 18 The EAC protocol used an optimized RT. 16, 19 The sensitivity was significantly improved using Moloney murine leukaemia virus (MMLV) enzyme or Superscript (Invitrogen, Carlsbad, CA, USA) and random primers at a final concentration of 25 mM. A comparison of reverse transcriptases in gene expression by Stahlberg et al., 20 which included Superscript III and MMLV, found that Superscript gave the overall highest yield and was the most efficient enzyme. Although BCR-ABL expression was not included in that study, the yields of other genes varied by up to 100-fold with the choice of reverse transcriptase. Avian myeloblastosis virus (AMV) gave the poorest yield. The EAC concluded that random primers gave more efficient cDNA synthesis than oligo-dT. 16 No difference was observed between hexamers and nonamers. Random primers are reported to produce the least bias in the resulting cDNA 21 and is a resource for use in other experiments such as BCR-ABL mutation analysis. A specific primer is inappropriate since the control and target undergo separate RT, which precludes compensation for the inherent differences in RT efficiency.
Appropriate standards and the influence of PCR amplification efficiency
The EAC concluded that DNA plasmids were suitable material for constructing standard curves. 16 This material is referred to here as calibration standards. RNA and cDNA were tested by the EAC but did not provide the stability and robustness of plasmids, although RNA has been used successfully. 3 It is essential that calibration standards be included in every PCR. Each reaction will produce variable data owing to probe degradation or different reagent batches. The calibration standards are affected to the same extent as the patient samples and will therefore compensate for the variation. Moreover, they will compensate for the small but significant day to day variation observed, even when the same reagents are used. 22 Plasmid calibration standards have proved valid even though they do not directly compensate for the variation in RT efficiency between reactions. This factor is accounted for by normalization to the control transcript measurement when random primers are used. However, this assumes that the plasmid calibration standard and the cDNA template have approximately equal amplification efficiencies. 23 This is an important factor for accurate results as different templates can amplify with different efficiencies when using the same PCR conditions, which could lead to result errors. 15, 24 Therefore, the assay validation process should include an examination of the amplification efficiencies. Harmonizing RQ-PCR methodology for BCR-ABL transcripts S Branford et al Amplification efficiency is calculated by performing serial dilutions over several orders of magnitude in triplicate. 25 The fractional cycle number when sample fluorescence reaches a predetermined threshold (C t ) is plotted against the log input of the copy number and the amplification efficiency calculated from the slope of the regression line using the formula (10 (À1/slope) )À1. This method is a simplified approach for efficiency calculation as the efficiency may change as the starting copy concentration varies and therefore may not be accurate. 26, 27 Nevertheless, the method is useful to compare relative amplification efficiencies. The acceptability of the relative efficiencies can be confirmed by demonstrating that when patient cDNA is diluted in a 10-fold series, the transcript values are not significantly different from the expected 1 log reduction at each dilution step. 15 
Quality assurance of the RQ-PCR assay
Normalizing BCR-ABL values to the control gene controls for the RT efficiency and compensates for RNA degradation; however, it does not provide assurance that the quantitative value is reliable. To recognize poor assay performance, it is essential to include samples in each run with a pre-determined range of acceptable values. These samples are particular reference materials, referred to here as quality controls (QC), which enable the operator to make an informed decision on the reliability of patient results. If the QC results fall outside of the acceptable range, then the patient results are rejected and the run is repeated. The QC closely mimic the biological material under investigation in terms of matrix composition, physical preparation and concentration range. Where possible, they undergo the same procedures as the patient samples, commencing at the RNA extraction stage. The QC samples are considered surrogates that assess the performance of the whole procedure, both within a run and over longer intervals. 28 This assessment includes the accuracy of the standard curve. Therefore, an appropriate QC must be independent of the calibration standards. QC that fit these criteria can be prepared on a large scale for long-term use by mixing positive and negative cells derived from cell lines grown using standard tissue culture techniques. 29 The cell mixtures are divided and stored in frozen aliquots after trizol RNA stabilization. The QC therefore undergo the same procedures as the patient samples.
QC at a value approximating an MMR is desirable as this level has proven clinical efficacy for imatinib therapy. QC at a value approximately 3 logs higher than MMR will assess the linearity of the assay.
BCR-ABL-negative QC and at least two levels of BCR-ABLpositive QC are required to monitor each RQ-PCR assay. 24, [29] [30] [31] [32] The negative QC monitors for cross-contamination introduced during RNA extraction or contamination of reagents. If contamination occurs, or the positive QC are outside the acceptable range, it indicates failure of a procedure and repeat analysis is required. 29 Acceptable QC ranges can be determined by repeat analysis over many runs to calculate the mean and standard deviation of the BCR-ABL/control% value. Multiple statistical control rules are applied for acceptance or rejection of runs. 15, 29, 33 The process of including QC to assess performance and determine RQ-PCR data acceptability is no different to that used to monitor all routine quantitative haematology or biochemistry assays. Appropriate QC for BCR-ABL quantitation are currently unavailable for commercial purchase, meaning that these samples need to be prepared by the laboratory performing the assay.
In addition to QC performed in every run, quality assurance of the RQ-PCR assay will require proficiency testing with external QC. This is periodic assessment of laboratory performance achieved by the distribution of appropriate testing materials by an independent body. 34 However, without the support of an internal QC system for a check on analytical processes, the benefits of proficiency testing are limited. 28 
Measurement reliability of the RQ-PCR assay
A prerequisite of analytical testing is recognition of 'fitness for purpose', meaning the standard of accuracy and reliability required for an effective use of the data. 28 For effective molecular monitoring in CML, it is necessary to distinguish a biologically significant change from a change owing to analytical variation. For example, an increase in BCR-ABL of greater than two-fold on consecutive analyses is associated with the detection of BCR-ABL mutations in imatinib-treated patients and can be used to trigger mutation analysis. 35 Therefore, a rise of just over two-fold may be biologically significant although not necessarily defining relapse. However, this is only valid when Harmonizing RQ-PCR methodology for BCR-ABL transcripts S Branford et al the standard of reliability of a particular assay has demonstrated a consistent ability to distinguish such a small change and may not be achievable outside of a specialized laboratory. Thus, to avoid misinterpretation of data, it is important that a statement of the measurement reliability (also known as uncertainty) accompany results or be readily available to clinicians using the data. 28 Measurement reliability generally describes the variability of results when the same sample is repeated in a separate run within the same laboratory. It is the measure of precision and defines the range around the experimentally determined result, which contains the true value. It is important to note that the ability of an assay to produce a mean result close to the true value defines the accuracy of analysis but does not imply acceptable precision. Precision can be expressed as the CV.
Although a consensus on acceptable CV has not been established, procedures can be implemented to optimize measurement reliability 35 such as performing replicate analysis, either at the RT or quantitative PCR step or both, and averaging results. When considering the experimental variation of each step, the variability of analysis is reduced when the sample is analysed in duplicate RT reactions.
2,17,18,36 Figure 2 demonstrates the improvement in precision when duplicate RT is performed. The organizational infrastructure of the whole analytical process must be well maintained to limit the experimental variation. This includes adequate training of operators, reliable reagent source and regular maintenance and calibration of pipettes and analysers.
An important determinant of reproducible RQ-PCR data is the coefficient of determination (R 2 ) of the standard curve. This factor describes the amount of variability in the y variable (quantitative value) that is explained by the variability in the x variable (C t ). The closer R 2 is to 1.0, the less scatter there is in the relationship between the C t and the quantitative value. It has been reported that slopes between -3.0 and -3.9 will probably be acceptable as long as R 2 is 40.95. 37 However, the data represented in Figure 3 and Table 1 demonstrate that a R 2 value close to 0.95 is indeed not acceptable and indicates poor assay reproducibility. For demonstration purposes, standard curve data was simulated by plotting theoretical C t values against theoretical log input values. The regression formulae are those mathematically generated by the theoretical data. The formula for the calculation of quantitative data is derived from the slope and intercept of the regression line (C t -intercept)/slope. From Table 1 , the difference between the triplicate C t values from Graph A (R 2 ¼ 0.9972) (Figure 3 ) ranged from 0.4 to 1.0, representing a transcript difference of 1.2-to 1.9-fold. The triplicate C t values from Graph B (R 2 ¼ 0.9505) varied considerably more, from 0.9 to 4.5, representing a difference of 1.7-to 19.4-fold. If significant variation occurs in the standard curve such that the R 2 value is 0.95, then one can only presume the same considerable scatter will occur in patient samples. Figure 3 The R 2 value of the standard curve gives an indication of result variability. The graphs have been simulated to demonstrate less scatter of triplicate analyses when R 2 is close to 1.0 (a) compared to 0.95 (b). Although the curves have similar slope and intercept, less scatter is desirable for improved precision of patient results. A change in C t of one represents approximately two-fold difference.
Table 1
The C t and calculated transcript values for each simulated curve and triplicate in Figure 3 , assuming 10-fold dilutions of 10 6 transcripts To determine measurement reliability, all procedural variables must be considered. In many reports, these measurements have been based on intra-or inter-assay CV of the C t values. However, this is inappropriate because C t values are logarithmic units and result in a misleading representation of reproducibility. 16, 38, 39 Measurement reliability should be based on the BCR-ABL/control gene ratio determined using repeated RT and quantitative PCR analyses of the same samples. As the QC material described above undergo the same processes as patient samples, their CV can be used to assess measurement reliability. This approach is a reasonably accurate reflection of patient variability, particularly if determined with different operators and reagent batches. Use of a valid method developed elsewhere does not guarantee achievement of its established performance characteristics. Therefore, measurement reliability must be determined in each laboratory, independent of the method used. This is to account for variability of all factors associated with the individual laboratory such as operators, RNA extraction procedure, instruments and reagent source. In the EAC studies, Beillard et al. 19 demonstrated that despite the use of common calibration standards and optimized RT and RQ-PCR protocols, several crucial variables were identified that resulted in overwhelming inter-laboratory variation.
The principle that an informed data interpretation requires knowledge of assay measurement reliability and that the reliability should fit the purpose of analysis is demonstrated in the following simulated example. A biologically significant rise in BCR-ABL transcripts occurs over 3 months in an imatinibtreated patient without a dose change, which may indicate emergent imatinib resistance. The true BCR-ABL/control% of the first sample is 0.5% and the true value when measured 3 months later is 2.5%. The ability to consistently detect a true rise in an individual laboratory is highly dependent on the reliability of the RQ-PCR assay. Assuming an accurate RQ-PCR assay has a CV of 20%, there is a 95% probability that the value for the first sample will fall within the range BCR-ABL/control% 0.30-0.70. There is a 95% probability that the second value will fall within the range 1.50-3.50. The probability that this assay will detect the rise between the first and second sampling time points is 99.95%. In this case, BCR-ABL mutation analysis is warranted. However, if an accurate but less reliable RQ-PCR assay has a CV of 45%, there is a 95% probability that the first value will fall within the range BCR-ABL/control% 0.05-0.95. There is a 95% probability that the second value will fall within the range 0.25-4.75. The probability that this assay will detect the rise is 81.2%, indicating less confidence for consistently detecting the rise. The current recommendation for mutation analysis is upon a confirmed rise in BCR-ABL. 40 Therefore, knowledge of the measurement reliability will aid in recognizing a rise, which for non-specialized laboratories may be five-fold.
Conclusion
The measures to limit the variability of RQ-PCR analysis are critically important if an assay is to distinguish a biologically significant change from a change owing to analytical variation. The inclusion of QC in each run that undergo the whole analytical process will identify failure of a procedure and indicate when repeat analysis is required. Appropriate levels of staff training and management, and instrument maintenance and calibration schedules must not be overlooked as these factors contribute to the achievement of the desired quality of data. Awareness by clinicians of the measurement reliability of the RQ-PCR assay that they are using is essential. The clinical significance of a result cannot be interpreted without this knowledge. 28 As the number of laboratories undertaking RQ-PCR analysis increases, the haematology community and commercial companies should work together to ensure that reliability of analysis and professional standards are not overshadowed by simplicity and convenience, which occurred when some test systems were introduced for Clinical Chemistry analysis over a decade ago. 41 With appropriate quality assurance, which includes external as well as internal quality control, and the availability of certified reference material in the future to enable local laboratories to express results on an International Scale, 13 accurate, reliable and sensitive RQ-PCR analysis should become the primary assay for monitoring response in CML.
